KIAA0101 interacts with BRCA1 and regulates centrosome number

Area of Science:

• Molecular Biology
• Genetics
• Cancer Research

Background:

• BRCA1 and BRCA2 proteins are crucial in DNA repair and maintaining genomic stability.
• Dysregulation of BRCA1/BRCA2 function is implicated in the pathogenesis of various cancers, particularly breast cancer.
• Identifying interacting partners of BRCA1/BRCA2 can elucidate mechanisms of cancer development.

Purpose of the Study:

• To identify novel genes and proteins collaborating with BRCA1 or BRCA2 in breast cancer pathogenesis.
• To investigate the functional role of the candidate interactor KIAA0101 in cancer development.
• To assess the clinical significance of KIAA0101 in human breast tumors.

Main Methods:

• Bioinformatic analysis to identify potential BRCA interactors.
• In vitro experiments to determine KIAA0101's effect on centrosome number and cell cycle.
• Immunofluorescence to confirm KIAA0101 localization at centrosomes.
• Co-immunoprecipitation assays to verify KIAA0101 binding to BRCA1.
• Tissue microarray analysis of human breast tumors to assess KIAA0101 expression levels and correlation with clinical biomarkers and patient survival.

Main Results:

• KIAA0101 was identified as a BRCA interactor with a significant role in controlling centrosome number, similar to BRCA1.
• KIAA0101's effect on centrosomes is direct, independent of cell cycle progression, and it binds to BRCA1.
• Overexpression of KIAA0101 in breast tumors correlated with positive Ki67 staining, indicating increased disease severity.
• Elevated KIAA0101 gene expression in breast tumors was significantly associated with decreased patient survival time.

Conclusions:

• KIAA0101 is a novel protein implicated in breast tumorigenesis through its control of centrosome number.
• The findings suggest a potential link between UV damage response pathways and centrosome regulation in breast cancer.
• KIAA0101 represents a potential therapeutic target and prognostic biomarker for breast cancer.